Cancer Immunology Immunotherapy,
Год журнала:
2025,
Номер
74(3)
Опубликована: Фев. 1, 2025
The
amazing
diversity
of
B
cells
within
the
tumor
microenvironment
is
basis
for
diverse
development
cell-based
immunotherapies.
Here,
we
focus
on
elucidating
mechanisms
intervention
mediated
by
four
tumor-infiltrating
lymphocytes.
Naive
present
initial
antigen,
germinal
center
cell
subsets
enhance
antibody
affinity,
and
immunoglobulin
subtypes
exert
multiple
immune
effects,
while
regulatory
establish
tolerance.
Together
they
reflect
complexity
changing
dynamics
cancer
immunity.
Additionally,
have
investigated
dynamic
effects
lymphocytes
in
immunotherapy
their
relationship
to
prognosis,
providing
new
insights
into
potential
treatment
strategies
patients.
B
lymphocytes
are
essential
mediators
of
humoral
immunity
and
play
multiple
roles
in
human
cancer.
To
decode
the
functions
tumor-infiltrating
cells,
we
generated
a
cell
blueprint
encompassing
single-cell
transcriptome,
cell-receptor
repertoire,
chromatin
accessibility
data
across
20
different
cancer
types
(477
samples,
269
patients).
cells
harbored
extraordinary
heterogeneity
comprised
15
subsets,
which
could
be
grouped
into
two
independent
developmental
paths
(extrafollicular
versus
germinal
center).
Tumor
extrafollicular
pathway
were
linked
with
worse
clinical
outcomes
resistance
to
immunotherapy.
The
dysfunctional
program
was
associated
glutamine-derived
metabolites
through
epigenetic-metabolic
cross-talk,
promoted
T
cell-driven
immunosuppressive
program.
These
suggest
an
intratumor
balance
between
germinal-center
responses
that
possibly
harnessed
for
cell-targeting
Cell,
Год журнала:
2024,
Номер
187(17), С. 4790 - 4811.e22
Опубликована: Июль 23, 2024
Characterizing
the
compositional
and
phenotypic
characteristics
of
tumor-infiltrating
B
cells
(TIBs)
is
important
for
advancing
our
understanding
their
role
in
cancer
development.
Here,
we
establish
a
comprehensive
resource
human
by
integrating
single-cell
RNA
sequencing
data
from
649
patients
across
19
major
types.
We
demonstrate
substantial
heterogeneity
total
abundance
subtype
composition
observe
immunoglobulin
G
(IgG)-skewness
antibody-secreting
cell
isotypes.
Moreover,
identify
stress-response
memory
tumor-associated
atypical
(TAABs),
two
tumor-enriched
subpopulations
with
prognostic
potential,
shared
pan-cancer
manner.
In
particular,
TAABs,
characterized
high
clonal
expansion
level
proliferative
capacity
as
well
close
interactions
activated
CD4
T
tumors,
are
predictive
immunotherapy
response.
Our
integrative
depicts
distinct
clinically
relevant
TIB
subsets,
laying
foundation
further
exploration
functional
commonality
diversity
cancer.
Abstract
Tertiary
lymphoid
structures
(TLS)
are
clusters
of
immune
cells
that
resemble
and
function
similarly
to
secondary
organs
(SLOs).
While
TLS
is
generally
associated
with
an
anti-tumour
response
in
most
cancer
types,
it
has
also
been
observed
act
as
a
pro-tumour
response.
The
heterogeneity
largely
determined
by
the
composition
tumour-infiltrating
lymphocytes
(TILs)
balance
cell
subsets
within
tumour-associated
(TA-TLS).
TA-TLS
varying
maturity,
density,
location
may
have
opposing
effects
on
tumour
immunity.
Higher
maturity
and/or
higher
density
often
favorable
clinical
outcomes
immunotherapeutic
response,
mainly
due
crosstalk
between
different
proportions
subpopulations
TA-TLS.
Therefore,
can
be
used
marker
predict
efficacy
immunotherapy
checkpoint
blockade
(ICB).
Developing
efficient
imaging
induction
methods
study
crucial
for
enhancing
integration
techniques
biological
materials,
including
nanoprobes
hydrogels,
alongside
artificial
intelligence
(AI),
enables
non-invasive
vivo
visualization
TLS.
In
this
review,
we
explore
dynamic
interactions
among
T
B
phenotypes
contribute
structural
functional
diversity
TLS,
examining
both
existing
emerging
induction,
focusing
immunotherapies
biomaterials.
We
highlight
novel
therapeutic
approaches
being
explored
aim
increasing
ICB
treatment
predicting
prognosis.
Phenomics,
Год журнала:
2023,
Номер
3(6), С. 549 - 564
Опубликована: Дек. 1, 2023
Abstract
It
is
widely
recognized
that
tumor
immune
microenvironment
(TIME)
plays
a
crucial
role
in
progression,
metastasis,
and
therapeutic
response.
Despite
several
noninvasive
strategies
have
emerged
for
cancer
diagnosis
prognosis,
there
are
still
lack
of
effective
radiomic-based
model
to
evaluate
TIME
status,
let
alone
predict
clinical
outcome
checkpoint
inhibitor
(ICIs)
response
hepatocellular
carcinoma
(HCC).
In
this
study,
we
developed
radiomic
status
within
the
prognosis
immunotherapy
A
total
301
patients
who
underwent
magnetic
resonance
imaging
(MRI)
examinations
were
enrolled
our
study.
The
intra-tumoral
expression
17
immune-related
molecules
evaluated
using
co-detection
by
indexing
(CODEX)
technology,
construct
Immunoscore
(IS)
with
least
absolute
shrinkage
selection
operator
(LASSO)
algorithm
Cox
regression
method
TIME.
Of
6115
features
extracted
from
MRI,
five
core
filtered
out,
Radiomic
(RIS)
showed
high
accuracy
predicting
testing
cohort
(area
under
curve
=
0.753).
More
importantly,
RIS
capability
anti-programmed
cell
death
1
(PD-1)
an
independent
advanced
HCC
0.731).
comparison
previously
models,
integrated
exhibits
not
only
higher
but
also
potential
guiding
significance
immunotherapy.
Frontiers in Immunology,
Год журнала:
2024,
Номер
15
Опубликована: Янв. 22, 2024
The
intricate
relationship
between
anti-tumor
immunity
and
autoimmunity
is
a
complex
yet
crucial
aspect
of
cancer
biology.
Tumor
microenvironment
often
exhibits
autoimmune
features,
phenomenon
that
involves
natural
the
induction
humoral
responses
against
self-antigens
during
tumorigenesis.
This
facilitated
by
orchestration
immunity,
particularly
within
organized
structures
like
tertiary
lymphoid
(TLS).
Paradoxically,
significant
number
patients
do
not
manifest
features
course
their
illness,
with
rare
instances
paraneoplastic
syndromes.
discrepancy
can
be
attributed
to
various
immune-mediated
locks,
including
regulatory
or
suppressive
immune
cells,
anergic
autoreactive
lymphocytes,
effector
cells
exhaustion
due
chronic
stimulation.
Overcoming
these
locks
holds
risk
induce
mechanisms
progression,
notably
observed
anti-immune
checkpoint
therapies,
in
contrast
more
conventional
treatments
chemotherapy
radiotherapy.
Therefore,
challenge
arises
managing
immune-related
adverse
events
(irAEs)
induced
inhibitors
treatment,
as
decoupling
them
from
activity
poses
clinical
dilemma.
review
summarizes
recent
advances
understanding
link
B-cell
driven
reactions
patients,
discusses
implications
this
relationship.
